Y-mAbs’ GD2-GD3 vaccine granted rare paediatric disease designation

12 December 2019 - Y-mAbs Therapeutics today announced that its GD2-GD3 vaccine has been granted a rare paediatric disease designation ...

Read more →

Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine

11 December 2019 - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine has ...

Read more →

2019-20 cost recovery implementation statement for PBS/NIP updated for 2018-19 financial outcome

12 December 2019 - The 2019–20 Cost Recovery Implementation Statement for the listing of medicines on the Pharmaceutical Benefits Scheme and ...

Read more →

Plans for measles vaccinations to be distributed back through PHARMAC

26 November 2019 - Measles vaccinations in the south will likely go back to being distributed by PHARMAC after being ...

Read more →

The life improvement value: a new measure of cost-efficiency

23 November 2019 - The decision not to make zoster vaccination available to people older than 79 years1 was based on ...

Read more →

Meningitis Foundation calls for PHARMAC to protect everyone

15 November 2019 - Following PHARMAC’s announcement stating the meningococcal ACWY vaccine will be available free from next month for ...

Read more →

PHARMAC widening access to the meningococcal ACWY vaccine

14 November 2019 - The meningococcal ACWY vaccine will be available free from next month for young people in close ...

Read more →

Merck’s Ervebo [Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP) live] granted conditional approval in the European Union

12 November 2019 - Authorisation represents significant advancement in the global response to Ebola. ...

Read more →

Johnson & Johnson announces submission of European marketing authorisation applications for Janssen’s investigational Ebola vaccine regimen

7 November 2019 - Data from multiple preclinical, Phase 1, 2 and 3 studies support applications, which have been granted Accelerated ...

Read more →

FDA approves Fluzone High-Dose quadrivalent (influenza vaccine) for adults 65 years of age and older

4 November 2019 - Will be available in fall 2020, in time for the 2020-2021 flu season. ...

Read more →

Report clearly demonstrates the value of vaccines

1 November 2019 - Medicines Australia welcomes today’s report from the Australian Institute of Health and Welfare which verifies the ...

Read more →

New Zealand Pharmaceutical Schedule - 1 November 2019

1 November 2019 - The November 2019 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

Benefit payments for Australian father cut while son receives cancer treatment

24 October 2019 - A Perth father has reportedly lost his Family Tax Benefit cut because his son wasn't vaccinated. ...

Read more →

Merck receives EU CHMP positive opinion for investigational V920 Ebola Zaire vaccine for protection against Ebola virus disease

18 October 2019 - Merck today announced that the CHMP of the EMA has adopted a positive opinion recommending a conditional ...

Read more →

Complexity in assessing the benefit versus risk of vaccines: experience with rotavirus and dengue virus vaccines

17 October 2019 - The remarkable contribution of immunisation programs to public health is recognised by most people, including those who ...

Read more →